Natalie Staplin

PhD

MRC PHRU Senior Statistician

Natalie is a Senior Statistician within the Renal Studies Group at the Clinical Trials Service Unit & Epidemiological Studies Unit (CTSU). She is also a lecturer on the MSc in Global Health Sciences. She joined CTSU in 2012 after completing an undergraduate degree in Mathematics with Actuarial Science and a PhD in Statistics. Her current research interests are epidemiological analyses of patients with chronic kidney disease to identify risk factors associated with vascular events or progression to end-stage renal disease. She is particularly interested in competing risks methodology and the use of directed acyclic graphs in observational analyses.

Recent publications

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
RECOVERY Collaborative Group None. et al, (2022)
UMOD-ulating CKD risk: untangling the relationship between urinary uromodulin, blood pressure, and kidney disease
Journal article

Turner M. and Staplin N., (2021), Kidney International, 100, 1168 - 1170
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article

RECOVERY Collaborative Group None., (2021), Lancet (London, England)
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Journal article

Horby PW. et al, (2021), Lancet Respiratory Medicine, 9, 1419 - 1426
Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.
Working paper

Horby P. et al, (2021), Lancet, 398